![]() At least 14 days should elapse between discontinuation of selegiline and initiation of treatment with a serotonergic drug.Įscitalopram increases toxicity of thioridazine by QTc interval. Selegiline and escitalopram both increase serotonin levels. Combination is contraindicated within 2 weeks of MAOI use. Procarbazine and escitalopram both increase serotonin levels. Contraindicated.Įscitalopram and pimozide both increase QTc interval. Phenelzine and escitalopram both increase serotonin levels. Leuprolide increases toxicity of escitalopram by QTc interval. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval. ![]() Lefamulin will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Isocarboxazid and escitalopram both increase serotonin levels. Goserelin increases toxicity of escitalopram by QTc interval. Contraindicated.Įscitalopram increases toxicity of dronedarone by QTc interval. Mild-to-severe: 10 mg/day clearance of racemic citalopram was decreased and plasma concentration were increased.Įscitalopram increases toxicity of cisapride by QTc interval.≥12 years: 10 mg PO qDay may increase dose after at least 3 weeks not to exceed 20 mg/day Dosage Modifications Renal impairment <12 years: Safety and efficacy not established Conversely, allow at least 14 days after stopping escitalopram before starting an MAOI.At least 14 days should elapse between discontinuation of an MAOI and initiation of escitalopram.Switching to or from a monoamine oxidase inhibitor (MAOI) used to treat for psychiatric disorders If intolerable symptoms occur following a dose reduction or discontinuation of treatment, then consider resuming the previously prescribed dose subsequently, continue decreasing the dose at a more gradual rate.Gradual dose reduction rather than abrupt cessation is recommended.Symptoms associated with discontinuation of SSRIs and SNRIs have been monitor for symptoms when discontinuing treatment.Mild-to-severe: 10 mg/day racemic citalopram clearance decreased resulting in increased plasma concentrationįor extended therapy, maintain at lowest effective dose and assess periodically the need for continued therapy Discontinuation of treatment.Severe: Use with caution insufficient number of patients have been evaluated during chronic escitalopram treatment.Mild-to-moderate: No dosage adjustment necessary.Secondary to panic disorder in women: 5-10 mg PO over 8 week period Vasomotor Symptoms Associated with Menopause (Off-label)ġ0 mg PO qDay may increase to 20 mg PO qDay after 4 weeks if symptoms not adequately controlled Dosage Modifications Renal impairment Secondary to Depression: 5-20 mg PO over 8 week period Indicated for acute treatment of generalized anxiety disorder (GAD)ġ0 mg PO qDay may increase to 20 mg/day after 1 week maintain at lowest effective dose and assess need of therapy periodically if extended therapy required Obsessive-Compulsive Disorder (Off-label)ġ0 mg PO qDay may increase to 20 mg/day after 1 week maintain at lowest effective dose and assess need of therapy periodically if extended therapy required Insomnia (Off-label) Indicated for acute and maintenance treatment of major depressive disorder (MDD)ġ0 mg PO qDay may increase to 20 mg/day after 1 week Generalized Anxiety Disorder
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |